Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510992 | 0.82 | ALOX5AP (0.36) | CHEK1ALOX5APALDH1A1CHEK2CNR1 | |
| SCHEMBL6518740 | 0.76 | CHEK1 (0.64) | CHEK1KCNH2PLK1LMNA | |
| SCHEMBL6509605 | 0.76 | CHEK1 (0.64) | CHEK1KCNH2PLK1LMNA | |
| SCHEMBL6508589 | 0.72 | CHEK1 (0.77) | CHEK1KCNH2PLK1 | |
| SCHEMBL6517703 | 0.70 | CHEK1 (1.00) | CHEK1KCNH2PLK1 | |
| SCHEMBL6516695 | 0.70 | CHEK1 (0.58) | CHEK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6507705 | 0.69 | CHEK1 (0.98) | CHEK1KCNH2PLK1 | |
| SCHEMBL6518149 | 0.69 | CHEK1 (1.00) | CHEK1KCNH2PLK1 | |
| SCHEMBL6515407 | 0.69 | CHEK1 (0.71) | CHEK1KCNH2PLK1 | |
| SCHEMBL6513819 | 0.69 | CHEK1 (0.71) | CHEK1KCNH2ALDH1A1PLK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885KCNH2 3052/4885ALOX5AP 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.